Cargando…
Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study
BACKGROUND: Orthotopic liver transplantation (OLT) is one of the most effective treatments for patients with hepatocellular carcinoma (HCC) within the Milan criteria. However, for patients beyond these criteria, the recurrence rate is higher and the prognosis is worse. Sorafenib is the only drug sho...
Autores principales: | Teng, Chieh-Lin, Hwang, Wen-Li, Chen, Yi-Ju, Chang, Kuang-Hsi, Cheng, Shao-Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359192/ https://www.ncbi.nlm.nih.gov/pubmed/22339891 http://dx.doi.org/10.1186/1477-7819-10-41 |
Ejemplares similares
-
Liver transplantation for hepatocellular carcinoma beyond the Milan criteria
por: Xu, Xiao, et al.
Publicado: (2016) -
Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria
por: Cho, Yuri, et al.
Publicado: (2017) -
Liver Transplantation Beyond Milan Criteria
por: Lingiah, Vivek A, et al.
Publicado: (2020) -
Living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria: outcome of expanded criteria in tumor size
por: Liang, Hsin-Rou, et al.
Publicado: (2021) -
Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome
por: Kornberg, A.
Publicado: (2014)